HRP20230147T1 - Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom - Google Patents
Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom Download PDFInfo
- Publication number
- HRP20230147T1 HRP20230147T1 HRP20230147TT HRP20230147T HRP20230147T1 HR P20230147 T1 HRP20230147 T1 HR P20230147T1 HR P20230147T T HRP20230147T T HR P20230147TT HR P20230147 T HRP20230147 T HR P20230147T HR P20230147 T1 HRP20230147 T1 HR P20230147T1
- Authority
- HR
- Croatia
- Prior art keywords
- particles
- microns
- formulation according
- bdp
- percent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 20
- 238000009472 formulation Methods 0.000 title claims 16
- 239000000843 powder Substances 0.000 title claims 3
- 239000003246 corticosteroid Substances 0.000 title 1
- 239000002245 particle Substances 0.000 claims 39
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 11
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 11
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims 8
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 229940112141 dry powder inhaler Drugs 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000027771 Obstructive airways disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960000193 formoterol fumarate Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000007561 laser diffraction method Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Formulacija suhog praška za upotrebu u inhalatoru za suhi prašak (DPI) sadrži sljedeće:
(a) udio fino usitnjenih čestica koje se sastoje od smjese sastavljene od 90 do 99.5 posto po masi fiziološki prihvatljivog ekscipijensa i 0.5 do 10 posto po masi magnezijeva stearata, gdje spomenuta smjesa ima prosječni promjer čestica manji od 20 mikrona,
(b) udio grubo usitnjenih čestica koje se sastoje od fiziokoški prihvatljivog ekscipijensa koji ima prosječni promjer čestica između 200 i 400 mikrona,
pri čemu je omjer fino usitnjenih čestica i grubo usitnjenih čestica između 1:99 i 30:70 posto po masi, te
(c) formoterol-fumarat dihidrat u kombinaciji s beklometazon-dipropionatom (BDP) kao aktivni sastojci oba u obliku usitnjenih čestica; gdje je doza od 6-12 µg formoterol-fumarat dihidrata koja se isporučuje po aplikaciji i doza od 100 ili 200 µg BDP koja se isporučuje se po aplikaciji i usitnjene čestice formoterol-fumarat dihidrata imaju sljedeću raspodjelu čestica:
i) ne više od 10% spomenutih čestica ima volumni promjer manji od 0.8 mikrona
ii) ne više od 50% spomenutih čestica ima volumni promjer manji od 1.7 mikrona, te
(iii) najmanje 90% spomenutih čestica ima prosječni volumni promjer manji od 5.0 mikrona, gdje su spomenute čestice formoterol-fumarat dihidrata naznačene time da je specifična površina od 5 do 7.5 m2/g i veličina čestica BDP u rasponu definiranom kao d(v,0.9) - d(v,0.1)]/d(v,0.5), jest između 1.2 i 2.2 m2/g i da je dalje naznačeno time da je specifična površina između 5.5 i 7.0 m2/g, pri čemu je specifična površina određena Brunaer-Tellerovom (BET) metodom adsorpcije dušika, te gdje:
i) ne više od 10% spomenutih čestica ima volumni promjer manji od 0.6 mikrona
ii) ne više od 50% spomenutih čestica ima volumni promjer između 1.5 i 2.0 mikrona, te
(iii) najmanje 90% spomenutih čestica ima prosječni volumni promjer jednak ili manji od 4.7 mikrona, a veličina čestica aktivnih sastojaka određena je metodom laserske difrakcije upotrebom Malevernovog instrumenta,
gdje fiziološki prihvatljiv akscipijens jest α-laktoza monohidrat.
2. Formulacija prema patentom zahtjevu 1, naznačena time da d(v,0.1) čestica BDP jest između 0.8 i 1.0 mikrona, d(v,0.5) u rasponu između1.5 i 2.0 mikrona i d(v,0.9) između 2.5 i 4.7 mikrona.
3. Formulacija prema patentom zahtjevu 2, naznačena time da veličina čestica BDP jest u rasponu između 1.3 i 2.1.
4. Formulacija prema patentnim zahtjevima 1-3, naznačena time da specifična površina čestica BDP jest između 5.9 i 6.8 m2/g.
5. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da omjer fino usitnjenih čestica a) i grubo usitnjenih čestica b) jest između 2:98 i 20:80 posto po masi.
6. Formulacija prema patentom zahtjevu 5, naznačena time da omjer jest 10:90 posto po masi.
7. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da udio fino usitnjenih čestica a) ima prosječnu veličinu čestica jednaku ili manju od 10 mikrona.
8. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da je veličina čestica grubo usitnjenih čestica b) jest između 212 i 355 mikrona.
9. Formulacija prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da usitnjene čestice formoterol-fumarat hihidrata imaju promjer koji je manji od 6 mikrona.
10. Formulacija prema patentnim zahtjevima 1-9, pri čemu su usitnjene čestice formoterol-fumarat dihidrata naznačno time da je specifična površina od 5.2 do 6.5 m2/g.
11. Formulacija prema patentom zahtjevu 10, pri čemu su usitnjene čestica formoterol-fumarat dihidrata naznačeno time da je specifična površina od 5.5 do 5.8 m2/g.
12. Formulacija prema patentom zahtjevu 1, sastoji se od sljedećeg:
(a) udio fino usitnjenih čestica koji se sastoji od smjese 98 posto po masi α-laktoza monohidrata i 2 posto po masi magnezijeva stearata, a spomenuta smjesa ima prosječni promjer čestica jednak ili manji od 6 mikrona,
(b) udio grubo usitnjenih čestica koji se sastoji od α-laktoza monohidrata koji ima prosječni promjer čestica između 212 i 355 mikrona, u kojem omjer fino usitnjenih čestica ili grubo usitnjenih jest 10:90 posto po masi, te
(c) formoterol-fumarat dihidrat u kombinaciji s beklometazon-dipropionatom (BDP) kao aktivni sastojci, a oba jesu u obliku usitnjenih čestica,
pri čemu se isporučuje doza od 6-12 µg formoterol-fumarat dihidrata po aplikaciji i isporučuje se doza od 100 ili 200 µg BDP po aplikaciji, te
i) ne više od 10% spomenutih čestica BDP ima volumni promjer manji od 0.7 mikrona,
ii) ne više od 50% spomenutih čestica ima volumni promjer između 1.6 i 1.9 mikrona, te
(iii) najmanje 90% spomenutih čestica ima volumni promjer manji od 4.0 mikrona.
13. Inhalator za suhi prašak je napunjen formulacijom suhog praška iz bilo kojeg od patentnih zahtjeva 1-12.
14. Formulacija prema bilo kojem od patentnih zahtjeva 1-12 za upotrebu u prevenciji i/ili liječenju upalne opstruktivne bolesti dišnih puteva.
15. Formulacija prema patentom zahtjevu 14, naznačena time da bolest jest astma ili kronična opstruktivna bolest pluća (COPD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152392 | 2012-01-25 | ||
| EP18181331.2A EP3412277B1 (en) | 2012-01-25 | 2013-01-23 | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230147T1 true HRP20230147T1 (hr) | 2023-03-31 |
Family
ID=47715987
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230147TT HRP20230147T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20221431TT HRP20221431T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20221433TT HRP20221433T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20221432TT HRP20221432T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20181550TT HRP20181550T1 (hr) | 2012-01-25 | 2018-09-28 | Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221431TT HRP20221431T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20221433TT HRP20221433T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20221432TT HRP20221432T1 (hr) | 2012-01-25 | 2013-01-23 | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom |
| HRP20181550TT HRP20181550T1 (hr) | 2012-01-25 | 2018-09-28 | Formulacija suhog praška koja sadrži kortikosteroid i beta-adrenergik za davanje inhalacijom |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10028964B2 (hr) |
| EP (7) | EP3527197B1 (hr) |
| JP (1) | JP6104282B2 (hr) |
| KR (3) | KR101895279B1 (hr) |
| CN (2) | CN105726548B (hr) |
| AR (1) | AR089805A1 (hr) |
| AU (1) | AU2013211656B2 (hr) |
| BR (1) | BR112014017481A8 (hr) |
| CA (1) | CA2862548C (hr) |
| CL (1) | CL2014001966A1 (hr) |
| CO (1) | CO7010836A2 (hr) |
| CY (1) | CY1120684T1 (hr) |
| DK (5) | DK3527199T3 (hr) |
| EA (2) | EA031566B1 (hr) |
| ES (5) | ES2928688T3 (hr) |
| FI (1) | FI3412277T3 (hr) |
| GE (1) | GEP201706767B (hr) |
| HK (1) | HK1200021A1 (hr) |
| HR (5) | HRP20230147T1 (hr) |
| HU (5) | HUE040525T2 (hr) |
| IL (1) | IL233784A0 (hr) |
| LT (5) | LT3412277T (hr) |
| MA (1) | MA35859B1 (hr) |
| MX (2) | MX355729B (hr) |
| MY (1) | MY165888A (hr) |
| NZ (1) | NZ627837A (hr) |
| PE (1) | PE20141703A1 (hr) |
| PH (1) | PH12014501565A1 (hr) |
| PL (5) | PL3412277T3 (hr) |
| PT (5) | PT2806855T (hr) |
| RS (5) | RS63761B1 (hr) |
| SG (1) | SG11201404350PA (hr) |
| SI (2) | SI3412277T1 (hr) |
| TN (1) | TN2014000322A1 (hr) |
| TW (1) | TWI559940B (hr) |
| UA (1) | UA115543C2 (hr) |
| WO (1) | WO2013110632A1 (hr) |
| ZA (1) | ZA201405464B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014017481A8 (pt) * | 2012-01-25 | 2021-06-15 | Chiesi Farm Spa | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação |
| KR20160029797A (ko) | 2013-07-11 | 2016-03-15 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
| UA118861C2 (uk) * | 2013-12-06 | 2019-03-25 | Оріон Корпорейшн | Спосіб отримання сухих порошкових композицій для інгаляцій |
| CA2962531C (en) | 2014-10-08 | 2023-05-23 | Eratech S.R.L. | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
| CN109789107B (zh) * | 2016-09-29 | 2021-12-03 | 广东东阳光药业有限公司 | 药物组合物 |
| PL3621590T3 (pl) * | 2017-05-11 | 2022-01-17 | Chiesi Farmaceutici S.P.A. | Sposób wytwarzania preparatu suchego proszku zawierającego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny |
| US11931368B2 (en) | 2017-09-29 | 2024-03-19 | Crititech, Inc. | Glucocorticoid “nintedanib” particles and their use |
| PT3833964T (pt) * | 2018-08-07 | 2023-08-17 | Norton Waterford Ltd | Aplicação de espetroscopia de raman para o fabrico de pós de inalação |
| US20210370007A1 (en) | 2018-10-30 | 2021-12-02 | Chiesi Farmaceuticl S.p.A. | Apparatus to administer drugs to mechanically ventilated patients |
| EP4034079A1 (en) | 2019-09-24 | 2022-08-03 | Chiesi Farmaceutici S.p.A. | Novel carrier particles for dry powder formulations for inhalation |
| AU2021324395A1 (en) | 2020-08-14 | 2023-03-16 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate |
| WO2023117967A1 (en) * | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| SK284889B6 (sk) * | 1998-11-13 | 2006-02-02 | Jago Research Ag | Použitie stearátu horečnatého v suchých práškových formuláciách na inhaláciu |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| ATE503517T2 (de) | 2002-07-31 | 2011-04-15 | Chiesi Farma Spa | Pulverinhalator |
| JO3102B1 (ar) * | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1944018A1 (en) * | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| WO2010097188A1 (en) * | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| US9101539B2 (en) * | 2009-05-15 | 2015-08-11 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| GB0914240D0 (en) * | 2009-08-14 | 2009-09-30 | Breath Ltd | Steroid solvates |
| WO2011038872A1 (en) * | 2009-10-02 | 2011-04-07 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate |
| EP2552424B1 (en) * | 2010-04-01 | 2018-05-09 | Chiesi Farmaceutici S.p.A. | Process for preparing carrier particles for dry powders for inhalation |
| ES2658179T3 (es) * | 2010-04-21 | 2018-03-08 | Chiesi Farmaceutici S.P.A. | Procedimiento para proporcionar partículas con cargas electrostáticas reducidas |
| BR112014017481A8 (pt) * | 2012-01-25 | 2021-06-15 | Chiesi Farm Spa | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação |
| KR20160029797A (ko) * | 2013-07-11 | 2016-03-15 | 키에시 파르마슈티시 엣스. 피. 에이. | 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제 |
-
2013
- 2013-01-23 BR BR112014017481A patent/BR112014017481A8/pt not_active Application Discontinuation
- 2013-01-23 WO PCT/EP2013/051187 patent/WO2013110632A1/en active Application Filing
- 2013-01-23 LT LTEP18181331.2T patent/LT3412277T/lt unknown
- 2013-01-23 HR HRP20230147TT patent/HRP20230147T1/hr unknown
- 2013-01-23 PT PT137043725T patent/PT2806855T/pt unknown
- 2013-01-23 AU AU2013211656A patent/AU2013211656B2/en active Active
- 2013-01-23 EA EA201690187A patent/EA031566B1/ru unknown
- 2013-01-23 PL PL18181331.2T patent/PL3412277T3/pl unknown
- 2013-01-23 RS RS20221007A patent/RS63761B1/sr unknown
- 2013-01-23 DK DK19167839.0T patent/DK3527199T3/da active
- 2013-01-23 PT PT181813312T patent/PT3412277T/pt unknown
- 2013-01-23 GE GEAP201313532A patent/GEP201706767B/en unknown
- 2013-01-23 ES ES19167775T patent/ES2928688T3/es active Active
- 2013-01-23 SG SG11201404350PA patent/SG11201404350PA/en unknown
- 2013-01-23 EP EP19167829.1A patent/EP3527197B1/en active Active
- 2013-01-23 LT LTEP13704372.5T patent/LT2806855T/lt unknown
- 2013-01-23 NZ NZ627837A patent/NZ627837A/en unknown
- 2013-01-23 EP EP13704372.5A patent/EP2806855B1/en active Active
- 2013-01-23 EP EP18181331.2A patent/EP3412277B1/en active Active
- 2013-01-23 HR HRP20221431TT patent/HRP20221431T1/hr unknown
- 2013-01-23 JP JP2014553692A patent/JP6104282B2/ja active Active
- 2013-01-23 PT PT191678291T patent/PT3527197T/pt unknown
- 2013-01-23 HU HUE13704372A patent/HUE040525T2/hu unknown
- 2013-01-23 RS RS20221033A patent/RS63759B1/sr unknown
- 2013-01-23 UA UAA201408448A patent/UA115543C2/uk unknown
- 2013-01-23 PL PL19167829.1T patent/PL3527197T3/pl unknown
- 2013-01-23 LT LTEP19167839.0T patent/LT3527199T/lt unknown
- 2013-01-23 KR KR1020177027831A patent/KR101895279B1/ko active IP Right Grant
- 2013-01-23 ES ES13704372.5T patent/ES2683254T3/es active Active
- 2013-01-23 CN CN201610080909.1A patent/CN105726548B/zh active Active
- 2013-01-23 ES ES19167839T patent/ES2929807T3/es active Active
- 2013-01-23 EP EP19167839.0A patent/EP3527199B1/en active Active
- 2013-01-23 PE PE2014001166A patent/PE20141703A1/es active IP Right Grant
- 2013-01-23 KR KR1020147019763A patent/KR101560288B1/ko active IP Right Grant
- 2013-01-23 SI SI201332032T patent/SI3412277T1/sl unknown
- 2013-01-23 HR HRP20221433TT patent/HRP20221433T1/hr unknown
- 2013-01-23 MX MX2014008631A patent/MX355729B/es active IP Right Grant
- 2013-01-23 HR HRP20221432TT patent/HRP20221432T1/hr unknown
- 2013-01-23 CN CN201380006645.XA patent/CN104080444B/zh active Active
- 2013-01-23 RS RS20181038A patent/RS57637B1/sr unknown
- 2013-01-23 ES ES18181331T patent/ES2938466T3/es active Active
- 2013-01-23 MY MYPI2014002176A patent/MY165888A/en unknown
- 2013-01-23 CA CA2862548A patent/CA2862548C/en active Active
- 2013-01-23 KR KR1020157019169A patent/KR101786586B1/ko active IP Right Grant
- 2013-01-23 RS RS20220971A patent/RS63706B1/sr unknown
- 2013-01-23 DK DK19167775.6T patent/DK3527196T3/da active
- 2013-01-23 HU HUE19167775A patent/HUE060402T2/hu unknown
- 2013-01-23 HU HUE19167829A patent/HUE060421T2/hu unknown
- 2013-01-23 US US14/417,484 patent/US10028964B2/en active Active
- 2013-01-23 MX MX2016001311A patent/MX368199B/es unknown
- 2013-01-23 EP EP19167775.6A patent/EP3527196B1/en active Active
- 2013-01-23 DK DK19167829.1T patent/DK3527197T3/da active
- 2013-01-23 PL PL13704372T patent/PL2806855T3/pl unknown
- 2013-01-23 EP EP19167835.8A patent/EP3527198A1/en active Pending
- 2013-01-23 PL PL19167775.6T patent/PL3527196T3/pl unknown
- 2013-01-23 RS RS20230066A patent/RS63952B1/sr unknown
- 2013-01-23 PT PT191677756T patent/PT3527196T/pt unknown
- 2013-01-23 FI FIEP18181331.2T patent/FI3412277T3/fi active
- 2013-01-23 LT LTEP19167829.1T patent/LT3527197T/lt unknown
- 2013-01-23 LT LTEP19167775.6T patent/LT3527196T/lt unknown
- 2013-01-23 DK DK13704372.5T patent/DK2806855T3/en active
- 2013-01-23 EP EP15202117.6A patent/EP3020394A1/en not_active Withdrawn
- 2013-01-23 DK DK18181331.2T patent/DK3412277T3/da active
- 2013-01-23 HU HUE19167839A patent/HUE060705T2/hu unknown
- 2013-01-23 EA EA201491281A patent/EA026267B1/ru unknown
- 2013-01-23 ES ES19167829T patent/ES2929137T3/es active Active
- 2013-01-23 PL PL19167839.0T patent/PL3527199T3/pl unknown
- 2013-01-23 SI SI201331186T patent/SI2806855T1/sl unknown
- 2013-01-23 PT PT191678390T patent/PT3527199T/pt unknown
- 2013-01-23 HU HUE18181331A patent/HUE061566T2/hu unknown
- 2013-01-24 US US13/748,882 patent/US8778402B2/en active Active
- 2013-01-24 TW TW102102606A patent/TWI559940B/zh active
- 2013-01-24 AR ARP130100225A patent/AR089805A1/es not_active Application Discontinuation
-
2014
- 2014-07-07 PH PH12014501565A patent/PH12014501565A1/en unknown
- 2014-07-11 MA MA37200A patent/MA35859B1/fr unknown
- 2014-07-24 CO CO14161092A patent/CO7010836A2/es unknown
- 2014-07-24 CL CL2014001966A patent/CL2014001966A1/es unknown
- 2014-07-24 ZA ZA2014/05464A patent/ZA201405464B/en unknown
- 2014-07-24 TN TNP2014000322A patent/TN2014000322A1/fr unknown
- 2014-07-24 IL IL233784A patent/IL233784A0/en active IP Right Grant
-
2015
- 2015-01-15 HK HK15100459.7A patent/HK1200021A1/xx unknown
-
2018
- 2018-06-22 US US16/015,666 patent/US10946029B2/en active Active
- 2018-09-11 CY CY181100948T patent/CY1120684T1/el unknown
- 2018-09-28 HR HRP20181550TT patent/HRP20181550T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230147T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20210704T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20211598T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20200260T1 (hr) | Pripravci, postupci i sustavi za respiratornu isporuku dva ili više aktivnih sredstava | |
| HRP20151214T1 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti | |
| ES2739352T3 (es) | Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol | |
| HRP20211599T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| CA2405767A1 (en) | Pharmaceutical formulations for dry powder inhalers | |
| JP2016512494A5 (hr) | ||
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| JP2013507429A5 (hr) | ||
| KR20130004236A (ko) | 의료품, 건조 분말 흡입기 및 폴리플럭스 충돌기 배열체 | |
| JP2015519356A5 (hr) | ||
| Hassoun et al. | Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers | |
| JP2018537453A5 (hr) | ||
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| EP2821061B1 (en) | Novel inhalation formulations | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| SA516371266B1 (ar) | طريقة لتحضير تركيبات استنشاق مسحوق جاف | |
| Momin et al. | Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide | |
| Vatanparast et al. | Efficiency improvement of fluticasone propionate dry powder formulation for inhalation in pulmonary patients | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. |